Dataset for clinical parameters and disease transcriptome networks associated with exposure to citalopram in zebrafish () larvae.

Citalopram, a selective serotonin reuptake inhibitor (SSRI), is often detected in aquatic ecosystems. In this investigation, developing zebrafish were continuously exposed to one nominal concentration of either 0, 10, or 1000 µg/L citalopram for 7 days. Ribonucleic acids were then extracted from zebrafish for RNA-sequencing using the NovoSeq 6000 (Illumina). Clean reads were obtained following the removal of both the adapter and poly-N sequences. Alignment and differential gene expression analysis was conducted using programs HISAT2 and StringTie assembler. Data were converted to FPKM to quantify differentially expressed transcripts. Significant clinical subnetworks enriched following citalopram exposure included sympathetic nerve activity, blood pressure, vascular tone, and arterial pressure. Regulated transcripts were related to diseases such as mechanical hyperalgesia, pain, inflammatory pain, obstructive hypertrophic cardiomyopathy, fatigue, Diamond-Blackfan anemia, and hypertrophic cardiomyopathy. Following exposure to 10 µg/L citalopram, several transcripts were linked to brain dysfunction like prostaglandin-endoperoxide synthase 2, microtubule associated protein tau, cathepsin B, and dystrophin. Genes related to cardiac dysfunction were altered in zebrafish following exposure to 1000 µg/L citalopram. Using literature and databases that describe gene interactions, molecular networks (clinical and disease networks) were constructed to understand effects of citalopram.